Search

Your search keyword '"Banks, Kimberly"' showing total 407 results

Search Constraints

Start Over You searched for: Author "Banks, Kimberly" Remove constraint Author: "Banks, Kimberly"
407 results on '"Banks, Kimberly"'

Search Results

2. The James Webb Space Telescope Mission

3. The Science Performance of JWST as Characterized in Commissioning

4. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations

5. Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients

6. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

7. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors

9. Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

10. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma.

11. Genomic landscape of cell-free DNA in patients with colorectal cancer

12. Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial

13. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

14. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing

15. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma

16. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary

17. The Mid-Infrared Instrument for JWST, II: Design and Build

18. Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer

19. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.

21. Genomic profile of advanced breast cancer in circulating tumour DNA

22. Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA

23. Multiomic analysis for minimal residual disease detection: Addressing challenges in stage II-III colon cancer from COSMOS-CRC-01.

24. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations

27. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

28. The James Webb Space Telescope Mission

29. The Science Performance of JWST as Characterized in Commissioning

30. Data from Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer

31. Supplementary Data from Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer

32. The Science Performance of JWST as Characterized in Commissioning

33. The Mid-infrared Instrument for JWST and Its In-flight Performance

34. Supplementary Figures 1,2, 3 from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

35. Table S1 from A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

36. Supplementary Table 1 from Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing

37. Figure S3 from A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

38. Table S3 from Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

39. Supplementary Figure 2 from Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

40. Supplementary Figure 1 from Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

42. Table S1 from Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies

43. Data from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

45. Supplemental Figure 2 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

46. Supplementary Data from Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

47. Supplemental Materials from The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients

48. Figure S4 from Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies

49. Supplemental Figure 1 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

50. Supplementary Figures S1, S2, S3 and Tables S1, S2 from Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Catalog

Books, media, physical & digital resources